The Theranos Scandal is an object lesson for the laboratory industry. It's not only an example of what NOT to do, but also an example of what we risk when we don't demand proof of quality, or what we might suffer if we don't prove the quality we're delivering. We don't want to be Theranosed. And we certainly don't want to be Theranosing others...
The official guide to developing IQCPs is finally out! What does it tell us about laboratory implementation of Risk Management for Quality Control? Do we even need the EP[tm] 23A guideline anymore?
With the expiration date on EQC drawing ever closer, US labs still await the details about its replacement. While CLSI EP23 has been public for more than a year, and CMS has made press releases about the new IQCP (Individualized Quality Control Plans) and has announced the benefits of this new forthcoming policy, the actual regulatory language has yet to be released or described.
On November 24th and 25th of 2014, the first EFLM Strategic Conference on 'Defining analytical performance goals 15 years after the Stockholm Conference on Quality Specifications in Laboratory Medicine' was held. The conference organizers released the official restructured hierarchy in 2015.
We've talked about Westgard Rules for decades, and we've talked about Six Sigma for years. So what happens when we try to talk about both at the same time? Westgard Sigma Rules
Probably the feature users will like least about the new Westgard Web is membership. In order to access some articles on the website, you'll need to become a member and login when you visit the website. But membership is free and the benefits of membership outweigh the hassle.